HOME >> MEDICINE >> NEWS
GlaxoSmithKline Drug Discovery and Development Award 2002

Six HIV and AIDS researchers will split $500,000 as this year's recipients of the GlaxoSmithKline (GSK) Drug Discovery and Development Award. The unrestricted research award program is funded by GSK to support independent, innovative and novel research in the development of HIV/AIDS therapeutics.

An Expert Review Board, composed of researchers who are leaders in the field of HIV/AIDS, independently judged and selected the award recipients. John A. Bartlett, M.D., professor of medicine at Duke University Medical Center; David D. Ho, M.D., professor at Rockefeller University and scientific director at Aaron Diamond AIDS Research Center; and Michael Saag, M.D., associate professor of medicine and director of the AIDS Outpatient Clinic at the University of Alabama at Birmingham, served on the board this year.

Recipients of the awards are Irwin Chaiken, Ph.D., University of Pennsylvania, Philadelphia, for his work studying the interactions between proteins that allow HIV to recognize and enter a host cell, research that potentially will lead to drugs that prevent the virus-cell fusion process; Nouri Neamati, Ph.D., University of Southern California School of Pharmacy, Los Angeles, for work in identifying the drug-binding site on HIV integrase, which should lead to development of second- and third-generation drugs that inhibit that enzyme; Alan C. Sartorelli, Ph.D., Yale University School of Medicine, New Haven, Conn., for his research on making certain enzyme inhibitors work more effectively; Nan-Sook Lee, Ph.D., Beckman Institute of the City of Hope, Duarte, Calif., for her research using gene therapy as a potential HIV/AIDS treatment; Elias Lolis, Ph.D., Yale University School of Medicine, for his work in attempting to solve likely side effects of some of the experimental entry inhibitor drugs; and Min Lu, Ph.D., Weill Medical College of Cornell University, New York, N.Y., for his research of a drug developed for herpes that may eventually be used for
'"/>

Contact: Elaine Salewske
esalewske@pcipr.com
312-558-1770
Public Communications Inc.
1-Oct-2002


Page: 1 2 3 4 5

Related medicine news :

1. TB Alliance announces new drug discovery program with GlaxoSmithKline
2. GlaxoSmithKline receives unanimous favorable recommendation by FDA Advisory Committee for Boostrix
3. Emory, GlaxoSmithKline, NIMH enter public-private partnership to develop new drugs for depression
4. GlaxoSmithKline Drug Discovery and Development Research Grant Program 2003
5. GlaxoSmithKline Drug Discovery and Development Research Grant Program 2003
6. GlaxoSmithKline Drug Discovery and Development Award 2002
7. Discovery of pathway in learning impairment caused by liver disease may lead to drug treatment
8. Discovery of key proteins shape could lead to improved bacterial pneumonia vaccine
9. Discovery of the oldest remains of a woman who died in childbirth
10. Discovery sheds light on how cancer cells grow and divide
11. Discovery changes ideas about damage from strokes

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: GlaxoSmithKline Drug Discovery and Development Award

(Date:5/20/2013)... Heritage Woods of Gurnee , a ... is hosting Breakfast and Bingo at 8:30 a.m. on ... at 3775 Grand Ave. in Gurnee, Illinois, serves older ... need some help to maintain their independence. , "Come ... bingo," says Tammy Temaner-Rosas, Director of Marketing for Heritage ...
(Date:5/20/2013)... MN (PRWEB) May 20, 2013 When a ... bed is only part of the process. Much of the ... the internet involves not knowing what to expect. Best ... advice consumers can use to ensure their purchase proves smooth. ... You Buy a Mattress Online ”, readers find helpful tips ...
(Date:5/20/2013)... 2013 Fastcare Miami Beach clinic ... within its first symptoms, as if not treated, it may ... serious infection. Although a urinary tract infection in itself is ... serious kidney infection called pyelonephritis. Women seem to have many ... to the same percentage as women after the age of ...
(Date:5/20/2013)... 20, 2013 Eben Pagan's ... the public creating a frenzy among business owners ... elite business training. WealthSpringMarketing.com's Tiffany Hendricks has published ... an exclusive bonus. , "Eben Pagan is a ... training to individuals serious about success," reports Hendricks. ...
(Date:5/20/2013)... May 20, 2013 Leading facial plastic surgeon ... recognized as a “Top Doc” in the field of Otolaryngology ... , The Palm Beacher magazine, one of Palm Beach ... Docs” in the May/June 2013 issue, including 70 of the ... and dining, events, things to do, health and fitness, people ...
Breaking Medicine News(10 mins):Health News:Heritage Woods of Gurnee Affordable Assisted Living Community to Host Breakfast and Bingo 2Health News:See What to Expect When You Buy a Mattress Online With Latest Guide From Best Mattress Online 2Health News:Fastcare Advises on How to Prevent a UTI 2Health News:Eben Pagan's Accelerate: Review and Bonus Released By WealthSpringMarketing.com 2Health News:Dr. Schwartz Named “Top Doc” by The Palm Beacher Magazine 2
(Date:5/20/2013)... ATLANTA , May 20, 2013  Atlantic ... developed and is commercializing a unique technology to ... founder and President, Anthony Soscia ... the Atlanta Business Chronicle ,s Health-Care Heroes ... Atlanta Business Chronicle to honor individuals and ...
(Date:5/20/2013)... May 20, 2013 Enrollment of patients with ... 2b dose-finding clinical trial of product candidate NewMet ... treatment for Type 2 diabetes. Elcelyx expects to complete ... in June. Results of the trial,s primary endpoint of ... summer, and the read-out for long-term glucose lowering and ...
(Date:5/20/2013)... Md. , May 20, 2013  Neuralstem, Inc. ... Feldman , MD, PhD, principal investigator, presented updated ... stem cell (NSI-566) trial in the treatment of amyotrophic ... ,s disease) at the neuro diabetes special medical symposium ... In a talk called "Recent Therapeutic Advances in Stem ...
Breaking Medicine Technology:Atlantic Pharmaceuticals President Named Health Care Hero Finalist in Atlanta Business Chronicle for Drug Abuse Deterrent Technology 2Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 2Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 3Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 4Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania 2Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania 3Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania 4
Cached News: